AbbVie Full Year 2025 Financial ReportAbbVieAbbVie reports strong 2025 results: revenue rises 9% to $61.2B, driven by Skyrizi and Rinvoq. Profits grow, international markets expand, and innovation sets stage for 2026.
Global Biopharma Layoffs November 2025LayoffsThis article tracks recent biotech and pharma layoffs, including major workforce cuts at Novo Nordisk, Takeda, GSK, Pharming, and others, as companies restructure operations, streamline pipelines, and refocus resources amid shifting market conditions.
AbbVie's Bold Claim: To Become the Largest CNS Company Next Year!AbbVieAbbVie sets its sights on becoming the top CNS company by 2026, driven by strong H1 growth, strategic acquisitions, and breakthrough treatments in neuroscience, including schizophrenia, migraine, and Parkinson’s disease.
AbbVie 2025 H1 ReportAbbVieAbbVie reports strong H1 2025 results with $28.77B in revenue, driven by autoimmune leaders Skyrizi and Rinvoq. Oncology and neuroscience segments also show solid growth and strategic expansions.
AbbVie's Q1 2025 Financial reportFinancial statementsAbbVie’s Q1 2025 report reveals soaring sales of Skyrizi and Rinvoq amid Humira’s decline. Explore how innovation, competition, and strategic shifts are reshaping AbbVie’s future in immunology and beyond.
2024 Global Top 10 Pharmaceutical CompaniesMarket TrendThe 2024 global ranking of the top 10 pharmaceutical companies showcases the continued strength of industry leaders like Johnson & Johnson, Roche, and Merck. Pfizer, AstraZeneca, and Eli Lilly also maintain strong positions with impressive growth and strategic investments.
Top 10 Pharmaceutical Giants' R&D Investments in 2024Market TrendIn 2024, pharmaceutical giants face a quiet battle over innovation and efficiency. From Merck’s 41% R&D drop to AbbVie’s bold growth, their strategies and investments reveal shifting power in the industry. A glimpse into the future of drug development.
2024 FDA Issued CRLsFDAThe FDA issued Complete Response Letters (CRLs) for multiple drug applications in 2024, citing concerns about efficacy, safety, and manufacturing. Learn about the rejected drugs, reasons behind CRLs, and their impact on pharmaceutical companies.
AbbVie 2024 Q4 Financial ReportFinancial statementsAbbVie’s 2024 financial report reveals strong growth with Skyrizi surpassing $10 billion in revenue, offsetting the decline of Humira. The company expects continued growth with new immunology deals and pipeline advancements.
Big Pharma -Waiting for the other Shoe to DropBiotechExplore the shifting landscape of big pharma as clinical trial results, patent cliffs, and innovative therapies shape 2025. Discover how giants like Eli Lilly, Pfizer, and Novo Nordisk navigate challenges and opportunities in weight loss, oncology, and vaccines.
EN
Agricultural News
Food News
Industrial News
Cosmetic News
Pharmaceutical News
Science News
